VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Several other research analysts have also recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of VolitionRx in a report on Wednesday, March 12th. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

VNRX stock opened at $0.55 on Thursday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.02. The company has a market capitalization of $50.97 million, a PE ratio of -1.53 and a beta of 1.09. The company’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.64.

Institutional Trading of VolitionRx

A number of institutional investors and hedge funds have recently made changes to their positions in VNRX. Northern Trust Corp raised its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of VolitionRx in the 4th quarter valued at $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter worth $36,000. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. boosted its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.